Publikationen, an denen er mitarbeitet JOSE LUIS MAURIZ GUTIÉRREZ (67)

2024

  1. Correction to: Protective Effect of Protocatechuic Acid on TNBS-Induced Colitis in Mice Is Associated with Modulation of the SphK/S1P Signaling Pathway (Nutrients, (2017), 9, 3, (288), 10.3390/nu9030288)

    Nutrients

  2. Corrigendum: Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells (Journal of Cellular Physiology, 10.1002/jcp.26855)

    Journal of Cellular Physiology

2023

  1. Correction to: Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells (Cancers, (2019), 11, 12, (1984), 10.3390/cancers11121984)

    Cancers

  2. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation

    Acta Pharmacologica Sinica, Vol. 44, Núm. 5, pp. 1066-1082

  3. Neuropilins as potential biomarkers in hepatocel-lular carcinoma: a systematic review of basic and clinical implications

    Clinical and Molecular Hepatology, Vol. 29, Núm. 2, pp. 293-319

2022

  1. Beneficial effects of melatonin on liver fibrosis: A systematic review of current biological evidence

    Journal of Cellular Physiology, Vol. 237, Núm. 7, pp. 2740-2757

  2. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

  3. Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies

    Cancers, Vol. 14, Núm. 14

2021

  1. Association of foxo3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: A systematic review with meta-analysis

    Cancers, Vol. 13, Núm. 21

  2. Autophagy-related chemoprotection against sorafenib in human hepatocarcinoma: Role of foxo3 upregulation and modulation by regorafenib

    International Journal of Molecular Sciences, Vol. 22, Núm. 21

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics

    Aging, Vol. 13, Núm. 19, pp. 23416-23434

  5. Melatonin as an antitumor agent against liver cancer: An updated systematic review

    Antioxidants, Vol. 10, Núm. 1, pp. 1-27

  6. Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

2019

  1. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers

    Experimental and Molecular Medicine, Vol. 51, Núm. 9

  2. Antitumor effects of quercetin in hepatocarcinoma in vitro and in vivo models: A systematic review

    Nutrients, Vol. 11, Núm. 12

  3. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease

    DMM Disease Models and Mechanisms, Vol. 12, Núm. 5

  4. Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells

    Cancers, Vol. 11, Núm. 12

2018

  1. Autophagy as a molecular target of flavonoids underlying their protective effects in human disease

    Current Medicinal Chemistry, Vol. 25, Núm. 7, pp. 814-838

  2. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells

    Journal of Cellular Physiology, Vol. 234, Núm. 1, pp. 692-708